3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Prostatic Neoplasms
31
Glioblastoma
28
Breast Neoplasms
20
Lung Neoplasms
17
Carcinoma, Non-Small-Cell Lung
16
Oropharyngeal Neoplasms
14
Squamous Cell Carcinoma of Head and Neck
11
Sarcoma
10
Esophageal Neoplasms
10
Urinary Bladder Neoplasms
9
Gliosarcoma
9
Glioma
9
Astrocytoma
9
Brain Neoplasms
8
Triple Negative Breast Neoplasms
7
Neoplasm Metastasis
7
Mouth Neoplasms
7
Uterine Cervical Neoplasms
6
Rectal Neoplasms
6
Melanoma
6
Head and Neck Neoplasms
6
Carcinoma, Hepatocellular
6
Carcinoma
6
Adenocarcinoma Of Esophagus
6
Stomach Neoplasms
5
Pancreatic Neoplasms
5
Neoplasms
5
Laryngeal Neoplasms
5
Carcinoma, Squamous Cell
5
Burkitt Lymphoma
5
Interventions
Carboplatin
5
pembrolizumab
3
Paclitaxel
3
Observation
3
Capecitabine
3
Azacitidine
3
venetoclax
2
pertuzumab
2
olaparib
2
durvalumab
2
Tretinoin
2
Trastuzumab
2
Standard of Care
2
Oxaliplatin
2
Irinotecan
2
Immunotherapy
2
Chemoradiotherapy
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
toripalimab
1
tislelizumab
1
tegafur-gimeracil-oteracil
1
taxane
1
talazoparib
1
tagraxofusp
1
sarilumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
Radiation
×
1 year
×
Clear all
NCT07472868
2026-03-16
MEND-IT II
Catharina Ziekenhuis Eindhoven
Phase 3
Not yet recruiting
394 enrolled